Prestige Consumer Healthcare Inc. $PBH Stake Lifted by Heartland Advisors Inc.

Heartland Advisors Inc. grew its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 41.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,376 shares of the company’s stock after acquiring an additional 18,851 shares during the quarter. Heartland Advisors Inc. owned about 0.13% of Prestige Consumer Healthcare worth $4,017,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of PBH. Caitong International Asset Management Co. Ltd grew its holdings in Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after buying an additional 250 shares in the last quarter. First Horizon Corp bought a new position in shares of Prestige Consumer Healthcare in the third quarter worth $32,000. Hantz Financial Services Inc. increased its holdings in shares of Prestige Consumer Healthcare by 373.6% during the third quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after purchasing an additional 538 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at about $46,000. Finally, First Horizon Advisors Inc. grew its position in Prestige Consumer Healthcare by 294.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after buying an additional 447 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 2,000 shares of company stock valued at $125,930. Corporate insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $66.32 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The company’s fifty day moving average is $64.07 and its 200-day moving average is $63.45. The firm has a market cap of $3.14 billion, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 2.10 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 12 month low of $57.25 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm’s revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on PBH shares. Oppenheimer lowered their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $80.60.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).